Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein

Tumor Biology

Volumn 24, Issue 6, 2003, Pages 317-324

  Okano, Kozue ^a   Fukui, Mikiko ^a   Suehiro, Yutaka ^a   Hamanaka, Yuichiro ^a   Imai, Kohzoh ^b   Hinoda, Yuji ^a,c  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Cancer immunotherapy; Peripheral blood mononuclear cells; Phytohemagglutinin; Transfection; Tumor antigen

Indexed keywords

CD8 ANTIGEN; CHROMIUM 51; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; LIPOSOME; MESSENGER RNA; PHYTOHEMAGGLUTININ; REAGENT; UNCLASSIFIED DRUG;

ADHERENT CELL; ARTICLE; ASSAY; CELL COUNT; CELL VIABILITY; COCULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DERIVATIZATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIPOFECTION; LYMPHOCYTE ACTIVATION; LYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET CELL; TECHNIQUE;

EID: 1542357611     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076464     Document Type: Article

References (27)

1. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
2. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.
3. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal BM, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
4. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement of activating Fc gamma receptors on dendritic cells. J Exp Med 2002;195:1653-1659.
5. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ: Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000;60:6995-7001.
6. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-6283.
7. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M: Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-3332.
8. Shimizu K, Fields RC, Giedlin M, Mule JJ: Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999;96:2268-2273.
9. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
10. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptidepulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
11. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186:1247-1256.
12. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
13. Mitchell DA, Nair SK: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-1069.
14. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000;164:5508-5514.
15. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16:364-369.
16. Boczkowski D, Nair SK, Snyder D, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-1034.
17. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
18. Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K: Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002;9:787-797.
19. Lundqvist A, Noffz G, Pavlenko M, Saeboe-Larssen S, Fong T, Maitland N, Pisa P: Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2002;25:445-454.
20. Steitz J, Bruck J, Gambotto A, Knop J, Tuting T: Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 2002;9:208-213.
21. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:89-93.
22. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994;153:2102-2109.
23. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-417.
24. Leshem B, Cohen I, Sherman L, Brautbar C, Kedar E: Typing of HLA class II and class I antigens using PHA-activated, IL-2-propagated T lymphocytes. J Immunol Methods 1998;111:131-135.
25. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 2000;7:2028-2035.
26. Grunebach F, Muller MR, Nencioni A, Brossart P: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003;10:367-374.
27. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA: Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552-1561.